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Health related quality of life after combined hormone
replacement therapy: randomised controlled trial
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research framework,1 Joseph Kim, statistician,2 Deborah Ford, senior statistician,3 Beverley A Lawton,
director women’s health research centre,4 Alastair H MacLennan, professor and head discipline of
obstetrics and gynaecology,5 Sarah K Meredith, senior clinical epidemiologist,3 Jeannett Martin, former
senior nurse manager,1 Tom W Meade, emeritus professor,2 for the WISDOM team
ABSTRACT
Objective To assess the effect of combined hormone
replacement therapy (HRT) onhealth relatedquality of life.
DesignRandomisedplacebo controlled double blind trial.
Setting General practices in United Kingdom (384),
Australia (94), and New Zealand (24).
Participants Postmenopausal women aged 50-69 at
randomisation; 3721 women with a uterus were
randomised to combined oestrogen and progestogen
(n=1862) or placebo (n=1859). Data on health related
quality of life at one year were available from 1043 and
1087 women, respectively.
Interventions Conjugated equine oestrogen 0.625 mg
plus medroxyprogesterone acetate 2.5/5.0 mg or
matched placebo orally daily for one year.
Main outcomemeasures Health related quality of life and
psychological wellbeing as measured by the women’s
health questionnaire. Changes in emotional and physical
menopausal symptoms as measured by a symptoms
questionnaire and depression by the Centre for
Epidemiological Studies depression scale (CES-D).
Overall health related quality of life and overall quality of
life asmeasuredby the Europeanquality of life instrument
(EuroQol) and visual analogue scale, respectively.
Results After one year small but significant improvements
were observed in three of nine components of the
women’s health questionnaire for those taking combined
HRT compared with those taking placebo: vasomotor
symptoms (P<0.001), sexual functioning (P<0.001), and
sleep problems (P<0.001). Significantly fewer women in
the combined HRT group reported hot flushes (P<0.001),
night sweats (P<0.001), aching joints and muscles
(P=0.001), insomnia (P<0.001), and vaginal dryness
(P<0.001) than in the placebo group, but greater
proportions reported breast tenderness (P<0.001) or
vaginal discharge (P<0.001). Hot flushes were
experienced in the combined HRT and placebo groups by
30% and 29% at trial entry and 9% and 25% at one year,
respectively. No significant differences in other
menopausal symptoms, depression, or overall quality of
life were observed at one year.
Conclusions Combined HRT started many years after the
menopause can improve health related quality of life.
Trial registration ISRCTN 63718836.
INTRODUCTION
The quality of an individual’s life is an important end
point in medical and health outcomes research.1 In
many circumstances quality of survival is as important
as quantity.2 Health related quality of life is a reflection
of the way patients feel or function. There is debate
about the effect of hormone replacement therapy
(HRT) on health related quality of life, though it has
been shown to improve general quality of life through
the reduction of both the number and severity of
menopausal symptoms.3 4
The perception of the risks and benefits of HRT and
its timing has changed dramatically since the publica-
tion of thewomen’s health initiative trial in 2002.5 That
study of women initiating HRT on average 13 years
after menopause did not find long term benefits on
cardiovascular outcomes, previously suggested by
observational studies of women initiating HRT near
menopause. The impact of HRT on patient centred
outcomes such as health related quality of life was
questioned.6 7Although the study reported a significant
benefit of combined oestrogen and progestogen
(combinedHRT) in health relatedquality of life related
to sleep disturbance, physical functioning, and bodily
pain, the differences were small, and for conjugated
equine oestrogen no effect was found in women who
had had a hysterectomy.7 The smaller heart and
oestrogen/progestin replacement study (HERS)
found that menopausal symptoms modified the effect
ofHRTonhealth relatedqualityof life:womenwithout
flushinghadgreaterdeclines in health relatedquality of
life related to physical measures, while those with
flushing experienced improvements in health related
quality of life related to emotional measures.8 Previous
studies have suggested that HRT has an important
positive impact on various symptoms of the meno-
pause and thus overall health related quality of life.4 9
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The two trials used generic instruments for measur-
ing quality of life, which are less sensitive to changes in
health related quality of life resulting from a particular
outcome or condition. Improvements in health related
quality of life attributable to the presence or absence of
postmenopausal symptoms might thus have been
overlooked as generic instruments do not contain
specific items on postmenopausal symptoms.10 Con-
dition specific instruments might be more appropriate
for use in a randomised controlled trial.11
The women’s international study of long duration
oestrogen after the menopause (WISDOM) aimed to
evaluate the long term benefits and risks of HRT.
WISDOM was a placebo controlled, double blind
randomised trial ofHRT inpostmenopausalwomen. It
aimed to randomise 22 300 postmenopausal women
aged 50-69 from primary care in the United Kingdom,
Australia, and New Zealand to HRT or placebo for a
median of 10 years. In addition to the main clinical
outcomes of cardiovascular disease, fractures, and
breast cancer, WISDOM included a detailed assess-
ment of the impact of HRT on health related quality of
life. Recruitment began in 1999 and continued until
October 2002, when the trial was closed after the
announcement that the women’s health initiative had
been terminated early because the risks of combined
HRT seemed to outweigh the benefits in that
population.5
We present findings from WISDOM for women
with an intact uterus or subtotal hysterectomy who
were randomised to combined HRT or placebo,
focusing on health related quality of life measured at
one year follow-up using both condition specific
measures designed specifically for postmenopausal
women and generic measures.
METHODS
Full details of the protocol, methods, and study
participants are described elsewhere.12-14 Participants
were recruited from general practices in the UK,
Australia, and New Zealand. Postmenopausal women
aged 50-69 at randomisation with an intact uterus or
subtotal hysterectomy were randomised to combined
HRT or placebo.14 Combined HRT was oral con-
jugated equine oestrogen 0.625 mg daily, plus oral
medroxyprogesterone acetate 2.5/5.0 mg daily (Pre-
mpro, Wyeth Ayerst, USA).
The trial was designed to treat participants for a
median of 10 years with scheduled visits at four weeks,
14 weeks, 27 weeks, 40 weeks, and 52 weeks, with
annual visits thereafter. All participants were encour-
aged to continue attending annual interviews whether
or not they had stopped taking study treatment. When
the study closed early the median follow-up time was
one year. After closure participants were asked to
continue taking study medication until they were able
to attend a clinic for a final visit, which included the
interview conducted annually, irrespective of a parti-
cipant’s time in the trial. This report is limited to data
collected a year after randomisation as information on
health related quality of life was available on less than
half of all study participants by the end of the second
year.
Outcome measures
Thewomen’s healthquestionnaire is designed to assess
physical and emotional wellbeing in middle aged
women.15 16 We used a modified version comprising a
five itemself esteemscale and items intended tocapture
eight components of women’s health: depressedmood
(seven items), somatic symptoms (seven items), mem-
ory and concentration (three items), vasomotor symp-
toms (two items), anxiety or fears (four items), sexual
functioning (three items), sleep problems (three items),
andmenstrual symptoms (four items).17 Each itemwas
rated on a four point scale: “yes, definitely”(1), “yes,
sometimes” (2), “no, not much” (3), and “no, not at all”
(4), and thiswas reduced to abinary scale—that is, 1 and
2 (coded 0) v 3 and 4 (coded 1) for scoring. For each
domain we computed the mean score for the corre-
sponding items, thus the higher the score, the better the
quality of life on that specific domain.
We assessed the prevalence of individual symptoms
related to menopause using a 28 item symptom
questionnaire that asked about the presence of
symptomsoccurring in thepast fourweeks.Depression
was assessedwith theCenter forEpidemiologic Studies
depression scale (CES-D), a 20 item self report
depression scale designed to measure the presence
and severity of depressive symptomatology in the
general population.18 19 Patients are presented with 20
statements and asked to indicate how they have been
feeling using four response options from “rarely or
noneof the time” to “mostor all of the time.”Responses
are scored from 0 to 3, where higher scores indicate
higher frequency (score ranges from 0 to 60). A higher
overall score indicates more severe depression; scores
above 16 are generally considered high.
The European quality of life instrument (EuroQoL)
is a twopart genericmeasureof health relatedquality of
life that has been validated for use in clinical trials.20 It
consists of the EQvisual analogue scale (EQ-VAS) and
anoverallhealth classification index (EQ-5D).21The10
centimetre EQ visual analogue scale ranged from 0
(“worst imaginable health state”) to 100 (“best imagin-
able health state”); participants are asked to grade their
current state of health (as opposed to the visual
analogue scale in which patients rate their overall
quality of life, not their health). The six item health
classification index assessed five unique dimensions of
health related quality of life: mobility, self care, usual
activities, pain/discomfort, and anxiety/depression.
Each dimension is measured on a three point ordinal
scale (that is, “no problem,” “some problem,” and
“extreme problem”) such that a higher score corre-
sponds to a worse state of health. Participants are then
effectively located into one of 243 possible health states
for which a global utility score is assigned. The utility
score has been previously determined based on the
preferences of a sample of 3395 individuals, represen-
tative of theUK general population.22 A utility score of
1 corresponds to the highest possible degree of health
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relatedqualityof life, and scoreof 0 is compatiblewith a
level equivalent to death. A negative utility score
corresponds to a state that is worse than death. The
EuroQoL has been previously validated in numerous
different settings.23-25
The visual analogue scale is a single item generic
measure designed to assess all aspects of life, not only
those that are health related.26 27 On a 10 centimetre
scale from 0 (“might as well be dead”) to 100 (“perfect
quality of life”), participants were asked “Which
number best represents your overall quality of life
over the past two weeks?”28
All measures were administered at baseline and at
annual visits. The visual analogue scale and symptoms
questionnaire were also administered at intermediate
follow-upvisits (that is, fourweeks, 14weeks, 27weeks,
and 40 weeks).
Statistical analysis
All analyses were intention to treat. Treatments were
comparedwithmultiple or logistic regression analyses,
including the measure of interest at baseline as a
covariate to adjust for any differences between treat-
ment groups at baseline. The geometric mean value
was used in the analysis of the CES-D data because the
distribution was right skewed. We evaluated the
possible modifying effect of baseline vasomotor
symptoms on effects of treatment at one year in health
related quality of life by fitting an interaction term(s).
Significance of the effect of combined HRT on
individual outcomes at one year was judged by
Bonferroni corrected α levels of 0.001 (about 0.05/
41). Interaction tests were performed only if we
identified a significant main effect and were used only
to look at associations with baseline vasomotor
symptoms. Analyses of visual analogue scales were
performed at each time point and within subgroups
with no adjustment formultiple testing. Text and tables
show unadjusted P values. All statistical analyses were
performed with Stata (version 9.2, College Station,
TX).
RESULTS
At the end of the trial 3721womenwith an intact uterus
or subtotal hysterectomy had been randomised, 1862
to combined HRT and 1859 to placebo.13 The figure
shows the flow of women after randomisation for this
report. We excluded women who had been in the trial
less than 40 weeks at trial closure in October 2002 or
who had died within one year of randomisation (total
671 combined HRT; 666 placebo). Of the remainder,
148 and 106 women randomised to combined HRT
and placebo, respectively, did not attend their one year
interview and cannot contribute to the primary
analyses (figure). Mean age at randomisation in the
2130 women in the primary analyses was 63.8 years
(SD4.4). Themedian time between randomisation and
one year interview was 368 days (90% interviews were
331-456 days after randomisation), and 21% of one
year interviews (21% combined HRT; 20% placebo)
were completed after trial closure.
At the first annual medical 290 (28%) women
randomised to combined HRT were no longer taking
trial treatment (214 had stopped permanently and 76
were on a temporary interruption of treatment). Of the
214 who stopped combinedHRT permanently, 91 did
so in the first 14 weeks and 177 did so in the first
27weeks.Overall, trial treatmentwas supplied for 79%
of follow-up time between randomisation and first
annual medical. Correspondingly, at the first annual
medical, 141 (13%) in the placebo group were not
taking trial treatment (89 had stopped permanently; 52
were on a temporary interruption); trial treatment was
supplied for 92%of follow-up time. Themost common
reasons for permanent discontinuation of combined
HRT were vaginal bleeding (68/214, 32%) and breast
tenderness (28/214, 13%).Of thepatientswhowerenot
taking trial treatment at the first annual medical, 174
(60%) in the combined HRT group and 10 (7%) in the
placebo group had previously reported bleeding to
some degree, including spotting. Of those taking trial
treatment at one year, 265 (37%) in the combinedHRT
group had reported bleeding at some time during the
first year, including 65 (9%) since their last visit.
Corresponding proportions in the placebo group were
36 (4%), including 9 (1%) since their last visit.
We reviewed the data on the women who did not
attend their one year interview and therefore could not
be included in the primary analyses.Most were known
to have discontinued trial treatment: 132/148 (89%)
women randomised to combined HRT stopped treat-
ment permanently before one year (n=118) or were on
a temporary interruption of treatment at one year
(n=14) and did not restart treatment before study
closure; in the placebo group 84/106 (79%) had
discontinued trial treatment (68 permanently and 16
on a temporary interruption). As in the women who
attended the one year interview, the most common
reasons for permanent discontinuation of combined
HRT were vaginal bleeding (42/118, 36%) and breast
tenderness (13/118, 11%.).
Randomised (n=3721)
Combined HRT (n=1862) Placebo (n=1859)
Died (n=2)Died (n=6)
n=1856 n=1857
n=1191 n=1193
In trial <40 weeks
at closure (n=664)
In trial <40 weeks
at closure (n=665)
Total for primary analyses
(n=1043)
Total for primary analyses
(n=1087)
Did not attend year 1
interview (n=106)
Did not attend year 1
interview (n=148)
Flow of participants after randomisation
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Women’s health questionnaire
According to assessment with the women’s health
questionnaire, participants in the combined HRT
group experienced significant improvements in vaso-
motor symptoms compared with the placebo group at
one year (difference between treatment groups,
adjusted for baseline score, 0.09, 95% confidence
interval 0.07 to 0.12), P<0.001) (table 1). Treatment
differences were more marked in those with more
severe baseline symptoms (P<0.001). Participants also
reported small but significant improvements related to
sexual functioning (difference between treatment
groups, adjusted for baseline score, 0.05, 0.02 to 0.08,
P<0.001) and sleep problems (difference between
treatment groups, adjusted for baseline score, 0.05,
0.02 to 0.07, P<0.001).Although sleepproblems at one
year were marginally higher in those with baseline
vasomotor symptoms, there was no evidence for a
difference in treatment benefit by baseline vasomotor
symptoms (P=0.78). Sexual function at one year was
not associated with baseline vasomotor symptoms
(P=0.78).
Menopausal symptoms
Table 2 shows the distribution of individual meno-
pausal symptomsby treatmentgroup.Atoneyear,with
adjustment for differences at baseline, participants
randomised to combined HRT experienced fewer
vasomotor symptoms, includinghot flushes (9% v 25%,
P<0.001) and night sweats (14% v 23%, P<0.001) than
those randomised toplacebo.Theywere also less likely
to report symptomsof aching joints andmuscles (57% v
63%, P=0.001), insomnia (35% v 41%, P<0.001), and
vaginal dryness (14% v 19%, P<0.001). Bloating was
marginally less prevalent in the combinedHRT group
than the placebo group (21% v 24%, P=0.005), but
significance was not achieved when we allowed for
multiple testing. The combined HRT group reported
higher rates of breast tenderness (16% v 7%, P<0.001)
and vaginal discharge (14% v 5%, P<0.001) than the
placebo group.
In a secondary analysis of symptoms at one year we
carried forward the last observation after entry for all
women without a one year interview who had been in
the trial at least 40 weeks at closure (allowing us to
include 99% of women in both treatment groups).
Overall results (not shown) were similar, although the
proportion of women reporting breast tenderness in
the combinedHRTgroup at their last visit whohadnot
attended a one year interview was somewhat higher
(48%, 64/133) than in the group interviewed at one
year (16%, 164/1043).
Vasomotor symptom interactions
We explored interactions between the treatment effect
at one year and baseline reporting of hot flushes or
night sweats. The benefit of combined HRT was
greater in those who had symptoms at baseline: at
one year in the combined HRT group 22% of those
who had reported hot flushes at baseline were still
having hot flushes compared with 65% in the placebo
group, while in women who had not reported hot
flushes at baseline corresponding proportionswere 4%
and 9%, respectively (interaction P=0.002). Similarly,
only 33% of women randomised to combined HRT
who reported night sweats at baseline were still having
them at one year compared with 62% of women
randomised to placebo; corresponding proportions of
those who had not reported night sweats at baseline
were 7% and 10% (interaction P=0.002). We investi-
gated whether the impact of combined HRT on other
symptoms varied according to baseline vasomotor
symptoms but found no interaction for aching joints
andmuscles, insomnia, vaginal dryness, breast tender-
ness, or vaginal discharge.
Depression
Assessment of depression with the CES-D at one year
showed no significant difference between the com-
bined HRT (median 3, interquartile range 0-7) and
placebo groups (median 3, 1-8; P=0.51 for difference,
adjusted for baseline score) and no difference in the
proportion of individuals who experienced high
Table 1 | Mean (SE) scores onhealth related quality of life asmeasuredwithwomen’s health questionnaire by treatment group
Component
Baseline One year
Adjusted† difference at
one year (95% CI) P value
Combined HRT
(n=1043*)
Placebo
(n=1087*)
Combined HRT
(n=1043*)
Placebo
(n=1087)*
Depression 0.803 (0.004) 0.797 (0.004) 0.803 (0.004) 0.805 (0.004) 0.00 (−0.01 to 0.01) 0.39
Somatic 0.755 (0.006) 0.764 (0.006) 0.775 (0.006) 0.781 (0.006) 0.00 (−0.02 to 0.01) 0.80
Memory 0.730 (0.010) 0.721 (0.009) 0.759 (0.009) 0.757 (0.009) 0.00 (−0.02 to 0.02) 0.88
Vasomotor 0.766 (0.012) 0.771 (0.011) 0.926 (0.007) 0.833 (0.010) 0.09 (0.07 to 0.12) <0.001‡
Anxiety 0.882 (0.006) 0.882 (0.006) 0.894 (0.006) 0.904 (0.006) 0.00 (−0.02 to 0.00) 0.18
Sexual 0.679 (0.012) 0.679 (0.013) 0.764 (0.0110 0.721 (0.012) 0.05 (0.02 to 0.08) <0.001‡
Sleep 0.637 (0.010) 0.657 (0.010) 0.740 (0.009) 0.703 (0.009) 0.05 (0.02 to 0.07) <0.001‡
Menstrual 0.906 (0.005) 0.905 (0.005) 0.905 (0.005) 0.907 (0.005) 0.00 (−0.01 to 0.01) 0.77
Esteem 0.546 (0.004) 0.544 (0.004) 0.559 (0.004) 0.553 (0.004) 0.00 (−0.01 to 0.02) 0.40
*No in each group at each time point for any measure except sexual function (n=591 for cHRT group (588 at one year) and 580 for placebo group (569
at one year) for women who attended interview).
†Adjusted for baseline score.
‡Significant at Bonferroni corrected α level of 0.001; actual unadjusted P values presented.
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depressive scores (CES-D >16 units) between the two
treatment groups (8% v 9%; P=0.51, adjusted for
baseline).
Quality of life
There were no differences in self assessed health
measured by the EQ visual analogue scale at one
year follow-up (table 3). Participants randomised to
combined HRT had a marginally higher health
Table 2 | Prevalence of symptoms related tomenopause. Figures are numbers (percentages) ofwomen
Symptom
Baseline One year Adjusted†
difference at one
year (95% CI) P value§
Combined HRT
(n=1041*)
Placebo
(n=1085*)
Combined HRT
(n=1043*)
Placebo
(n=1087*)
Hot flushes 317 (30) 311 (29) 98 (9) 269 (25) −15 (−18 to −12) <0.001‡
Night sweats 283 (27) 281 (26) 145 (14) 252 (23) −9 (−13 to −6) <0.001‡
Insomnia 471 (45) 472 (44) 367 (35) 450 (41) −6 (−10 to −2) <0.001‡
Feeling depressed 195 (19) 207 (19) 234 (22) 256 (24) −1 (−5 to 2) 0.6
Feeling anxious 293 (28) 284 (26) 300 (29) 313 (29) 0 (−4 to 4) 0.7
Dizziness 117 (11) 137 (13) 133 (13) 143 (13) 0 (−3 to 2) 1
Aching joints or
muscles
659 (63) 680 (63) 592 (57) 688 (63) −7 (−11 to −2) <0.001‡
Tiredness 523 (50) 516 (48) 556 (53) 554 (51) 2 (−2 to 7) 0.5
Headache 264 (25) 288 (27) 268 (26) 273 (25) 1 (−3 to 4) 0.6
Migraine 44 (4) 56 (5) 51 (5) 60 (6) −1 (−3 to 1) 0.8
Irritability/mood
swings
181 (17) 183 (17) 186 (18) 220 (20) −2 (−6 to 1) 0.1
Heart racing or
skipping beats
114 (11) 112 (10) 149 (14) 128 (12) 2 (0 to 5) 0.1
Dry skin or scaling 319 (31) 332 (31) 304 (29) 326 (30) −1 (−5 to 3) 0.6
Vaginal or genital
dryness
249 (24) 244 (22) 150 (14) 211 (19) −5 (−8 to −2) <0.001‡
Vaginal or genital
itching
115 (11) 101 (9) 121 (12) 118 (11) 1 (−2 to 3) 0.9
Vaginal or genital
discharge
58 (6) 48 (4) 151 (14) 55 (5) 9 (7 to 12) <0.001‡
Pain or burning while
urinating
31 (3) 31 (3) 36 (3) 39 (4) 0 (−2 to 1) 0.8
Breast tenderness 65 (6) 69 (6) 164 (16) 76 (7) 9 (6 to 11) <0.001‡
Leg cramps in one leg 96 (9) 108 (10) 122 (12) 113 (10) 1 (−1 to 4) 0.3
Leg cramps inboth legs 169 (16) 167 (15) 227 (22) 205 (19) 3 (−1 to 6) 0.1
Swelling in one leg 45 (4) 35 (3) 44 (4) 31 (3) 1 (0 to 3) 0.2
Swelling in both legs 96 (9) 80 (7) 82 (8) 98 (9) −1 (−4 to 1) 0.07
Nausea 85 (8) 87 (8) 84 (8) 91 (8) 0 (−3 to 2) 0.8
Abdominal cramps 70 (7) 76 (7) 81 (8) 95 (9) −1 (−3 to 1) 0.4
Bloating 235 (23) 217 (20) 215 (21) 260 (24) −3 (−7 to 0) 0.005
Skin rash/itching 185 (18) 166 (15) 187 (18) 177 (16) 2 (−2 to 5) 0.6
Crawling feelingsunder
skin
83 (8) 81 (7) 77 (7) 76 (7) 0 (−2 to 3) 0.8
Trouble seeing not
corrected by glasses/
contact lenses
46 (4) 54 (5) 51 (5) 64 (6) −1 (−3 to 1) 0.4
*No of women with available data.
†Adjusted for baseline presence of symptom.
‡Significant at Bonferroni corrected α level of 0.001; actual unadjusted P values presented.
Table 3 | EuroQoL scores by treatment group. Figures aremeans (SE)
Baseline One year
Adjusted† difference
at one year (95% CI) P value
Combined HRT
(n=1042*)
Placebo
(n=1083*)
Combined HRT
(n=1043*)
Placebo
(n=1087*)
EQ-VAS 79.2 (0.4) 79.4 (0.4) 77.9 (0.5) 78.5 (0.4) −0.59 (−1.66 to 0.47) 0.28
EQ-5D 0.877 (0.005) 0.874 (0.005) 0.888 (0.005) 0.870 (0.005) 0.016 (0.003 to
0.028)
0.02
*No of women with available data.
†Adjusted for baseline score.
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classification index score compared with those rando-
mised to placebo (difference between treatment groups
adjusted for baseline score 0.016 units, 95%confidence
interval 0.003 to 0.028, P=0.02) but the difference was
not significant when we applied the Bonferroni
correction.
Generic visual analogue scale
At fourweekswomen in the combinedHRTgrouphad
a slightly lower overall quality of life than those in the
placebo group (difference, adjusted for baseline values,
−1.6 units, −2.7 to −0.4, P=0.006, table 4). This
difference was reduced at 14 weeks (P=0.03), and there
were no differences between the combined HRT and
the placebo groups after 14weeks.We lacked power to
investigate the extent to which the early reduction in
visual analogue score associated with combined HRT
declined because women who experienced a negative
impactof combinedHRTonqualityof life stopped trial
treatment early. The difference between treatment
groups at four weeks was somewhat greater in women
who stopped trial treatment before their first annual
medical (difference −2.6 units, −5.4 to 0.2) than in
women who were on trial treatment at one year
(difference−1.0 units,−2.2 to 0.2, P=0.3 for difference).
We repeated analyses using all available data at each
interview (onparticipants randomisedat least 40weeks
before closure) and found similar results (treatment
difference at four weeks −1.35 units, P=0.012; 1137
patients in the combinedHRTgroupand1141patients
in the placebo group).
DISCUSSION
In this randomised controlled trial women who started
taking combined HRT many years after menopause
experienced improved sleep and reduced vasomotor
symptoms. They also reported fewer aching joints and
muscles, less vaginal dryness, and improved sexual
functioning, but breast tenderness and vaginal dis-
charge increased. The beneficial changes in sleep and
sexual functioningwere independent of thepresenceof
baseline vasomotor symptoms (flushes or night
sweats). For most other condition specific measures
there were no differences between placebo and
combined HRT groups.
These improvements in health related quality of life
for postmenopausalwomenwere detected by using the
outcome specific women’s health questionnaire and a
symptoms questionnaire. There were no significant
changes, however, in health related quality of life
identifiedwith the genericEuroQoLor in quality of life
with the visual analogue scale. The former condition
specific questionnaires might be more sensitive to
menopausal changes influencing quality of life.
Comparison with published data
The improvements seen in WISDOM are consistent
with results from the women’s health initiative,
showing improvement in vasomotor symptoms,
sleep, and bodily pain after one year of combined
HRT.6 Self reported sleep problems have been
associated with both the perimenopause and postme-
nopause. Disturbed sleep can result in daytime
sleepiness, which in turn can increase the risk of
accidents, lead to underperformance in the workplace,
and affect the family and quality of life.29 Inadequate
sleep is also associated with an increased risk of
illnesses such as obesity, diabetes, hypertension, and
cardiovascular disease.30-32 Reducing sleep deprivation
might therefore have considerable health benefits.
Aches and stiff joints are commonly reported by
menopausal women, and self reported arthritis is
associated with menopausal status.33 A follow-up
studywith participants in the women’s health initiative
that looked at joint symptoms showed a higher
prevalence of pain or stiffness in those women who
stopped taking combined HRT compared with
placebo.34 Animal models also suggest that oestrogen
has an anaesthetic role and might prevent cartilage
erosion such as occurs in osteoarthritis.35-37
For women taking combined HRT there was a
significant improvement on the three item sexual
functioning domain of the menopause specific
women’s health questionnaire. It is difficult to compare
this finding with the women’s health initiative,
particularly as it has been argued that the single
question screen for sexual satisfaction used in the
women’s health initiative was inadequate.38 The
WISDOM result is consistent with the recent findings
from the COGENT study, a randomised controlled
trial using combined HRT (conjugated equine oestro-
gen 0.625 mg/medroxyprogesterone acetate 2.5 mg )
for four months, which showed women treated with
combinedHRThad an increase in sexual thoughts and
interest compared with placebo.39 These women were
aged 45-55 years. The improvement in sexual
Table 4 | Differences in generic visual analogue scale for overall quality of life between treatment groups
Combined HRT Placebo Mean (95% CI)
difference between
treatment groups* P value*No with data Mean (SE) No with data Mean (SE)
Baseline 1042 78.1 (0.4) 1083 78.1 (0.4) — —
4 weeks 1009 74.9 (0.5) 1049 76.3 (0.4) −1.6 (−2.7 to −0.4) 0.006
14 weeks 951 74.9 (0.5) 1051 76.0 (0.4) −1.3 (−2.4 to −0.1) 0.03
27 weeks 878 75.7 (0.5) 1035 75.6 (0.5) −0.2 (−1.4 to 1.0) 0.78
40 weeks 827 75.6 (0.5) 983 75.7 (0.5) −0.2 (−1.4 to 1.1) 0.79
52 weeks 1041 77.1 (0.5) 1086 77.4 (0.4) −0.5 (−1.6 to 0.7) 0.42
*Adjusted for baseline score.
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functioning noted in the older age group studied in
WISDOMwarrants further investigation.
NeitherWISDOMnor thewomen’s health initiative
found an effect of combined HRT on depression
measured by CES-D. In WISDOM, the depression
component of the women’s health questionnaire also
showed no difference between combined HRT and
placebo groups. Two randomised controlled trials
involving older women found no effect of HRT on
depression.40 41 Two small randomised controlled trials
have shown a benefit of oestradiol in depressed
perimenopausal women.42 43 It is possible that any
antidepressant effect of oestrogen seen in women at or
near the menopause might be related to reduction of
menopausal symptoms.
About 22% of all women in the trial complained of
bloating at trial entry. This symptom might reflect
other common postmenopausal conditions such as
irritable bowel syndrome, peritoneal adhesions, and
increasing central obesity. While HRT has sometimes
been blamed for bloating in individual patients or in
uncontrolled series, in this study combined HRT did
not worsen bloating.
Weaknesses of study
Loss to follow-up and considerable discontinuation of
study medication, particularly in the combined HRT
group, were weaknesses that might have introduced
selection bias. Because of premature closure of the trial
around 36% of women in both treatment groups had
not reached 40 weeks of treatment at closure and were
excluded from all analyses in this paper. One year data
were not available for 12% of women randomised to
combined HRT and 9% of women randomised to
placebo at least 40 weeks before trial closure. Most
participants who did not attend a one year interview
had stopped study treatment, so it is likely that their
inclusion in an intention to treat analysis would have
reduced the treatment effects we observed. Non-
attenders at one year, however, might have had a
different symptom profile and overall quality of life
than attenders, and therefore some degree selection
bias is possible.
Participants who attended a one year interview but
were no longer taking treatment in the combinedHRT
group experienced more side effects early in the trial
than those who remained on treatment, specifically
bleeding and breast tenderness. Many similar com-
bined HRT regimens are associated with early bleed-
ing that mostly disappears over the first months of
treatment.44 Overall, the effect of early bleeding and
breast tenderness with combined HRT, causing
women to preferentially discontinue treatment, might
largely explain the reduction in quality of life as
assessed by the visual analogue scale score at 4 and
14 weeks of treatment. Even in those women who
remained taking treatment, however, therewas a small,
non-significant drop in quality of life at four weeks in
the combined HRT group compared with placebo,
suggesting a small true early adverse effect. Our study
lackedpower to showwhether the effect differs in those
who keep taking treatment and those who stop.
In the placebo group some of those who stopped the
study medication might have started HRT outside the
trial, although of the 89 patients on placebo who
stopped taking trial treatment permanently, only five
did so because theywanted to takeHRT. It is likely that
both side effects and benefits of combined HRT are
greater than estimated in patients who keep taking
treatment.
The impact of the early closure of WISDOM is
difficult topredict.Over a fifth (21%)of interviewswere
after closure, and participants’ responses might have
been influenced by the publicity surrounding closure
and by the knowledge that the trial was closing.
While the size of the differences in health related
quality of life was small, the presence of improvements
in sleep, aching joints, and relief of menopause
symptoms is consistent across other studies, including
the women’s health initiative, and these might be
important benefits formany symptomaticwomen.The
WISDOM results are limited by the relatively short
duration of follow-up and therefore we cannot say
whether these benefits would be maintained over a
longer treatment time or whether symptoms would
return after cessation of treatment as was seen for joint
pains in the women’s health initiative.34
Relevance of findings
The results of WISDOM are clinically relevant for
doctors treating postmenopausal womenwith relevant
symptoms including vasomotor symptoms, sleep
disturbance, and aching joints and muscles. When
women start combined HRT many years after the
menopause they must balance the risk of increased
cardiac events, venous thromboembolism, and breast
cancer against possible benefits on health related
quality of life.5 14 They must also consider possible
early side effects of combined HRT such as breast
tenderness, vaginal discharge, and uterine bleeding,
which usually resolve with time or dose titration.14
These side effects are common hyperoestrogenic
symptoms and might reflect the fixed dose regimen
in this trial, which was relatively high for women aged
over 60.
These results should be interpreted with caution, as
the presence of statistical significance does not imply
clinical significance.45 Differences between treatments
formost of the health related quality of lifemeasures in
this study were small, with the exception of improve-
ments related to vasomotor symptoms, and most
measures were not affected by combined HRT.
Conversely, because WISDOM and previous rando-
mised controlled trials such as the women’s health
initiative and the heart and oestrogen/progestin
replacement study (HERS) included women well past
the menopause who were mainly asymptomatic, the
results of these trials are likely to underestimate the
positive effects of combined HRT on health related
quality of life for women with symptoms. There is
much background literature and guidelines that
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support the premise that women with debilitating
menopause symptoms will have the most benefit in
health related quality of life from treatment with
combined HRT.46 47 This is an important message to
convey to women with severe menopausal symptoms.
Additionally, foryoungerwomen, recentdata suggest a
more favourable risk profile for combined HRT when
it is started within a few years of menopause compared
with many years after.48-50
The women’s health initiative (and to a lesser extent
WISDOM) have helped to answer the question as to
whether some chronic diseases could be prevented or
ameliorated when combined HRT is started many
years after the menopause. Chronic disease outcomes
should not be considered in isolation fromoutcomes of
health related quality of life in this age group.
Relevance for public health
The public health implication of our findings is that
combinedHRTmight improve some aspects of health
related quality of life in the late menopausal phase in
women with and without classic vasomotor menopau-
sal symptoms. Combined HRT improves sleep, aches
andpains, and sexual functioning.These gains cannow
be factored in to a woman’s choice to use combined
HRT. This benefit must be weighed against the overall
short and long term risks,whichmust be individualised
for women based on years since menopause, medical
history, and chosen regimen. Further research with
appropriatemeasures is needed to assessmore fully the
impact of combined HRT on all aspects of health
related quality of life for postmenopausal women. In
light of the WISDOM findings on quality of life
consideration should be given to revisiting HRT
guidelines.
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